 Alector Inc NASDAQ: ALEC and GlaxoSmithKline plc NYSE: GSK have announced a global collaboration for the development and commercialization of two monoclonal antibodies designed to elevate progranulin PGRN levels. PGRN is a crucial regulator of immune activity in the brain with genetic links to multiple neurodegenerative disorders. 